Literature DB >> 10906838

Physician prescribing of sterile injection equipment to prevent HIV infection: time for action.

S Burris1, P Lurie, D Abrahamson, J D Rich.   

Abstract

Injection drug users, their sex partners, and their children are at high risk for acquiring HIV infection and other bloodborne diseases. The risk for disease transmission in the United States is partly the result of restricted access to sterile injection equipment. Physicians and pharmacists can play an important role in providing syringe access by prescribing and dispensing syringes to patients who use injection drugs and cannot or will not enter drug treatment Prescribing and dispensing injection equipment are ethical, clinically appropriate, and fully consistent with current public health guidelines on disease prevention. An analysis of the laws of the 50 U.S. states, the District of Columbia, and Puerto Rico finds that physicians in nearly all these jurisdictions may legally prescribe sterile injection equipment to prevent disease transmission among drug-using patients and that pharmacists in most states have a clear or reasonable legal basis for filling the prescriptions. Given these medical and legal findings, physicians may wish to take a larger role in improving access to sterile injection equipment by prescribing this equipment for their patients where this practice is legal, and by joining efforts to change the law where it poses a barrier.

Entities:  

Mesh:

Year:  2000        PMID: 10906838     DOI: 10.7326/0003-4819-133-3-200008010-00015

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  14 in total

1.  Unintended subcutaneous and intramuscular injection by drug users.

Authors:  C Hankins; D Palmer; R Singh
Journal:  CMAJ       Date:  2000-11-28       Impact factor: 8.262

2.  Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

Authors:  B R Edlin; K H Seal; J Lorvick; A H Kral; D H Ciccarone; L D Moore; B Lo
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

Review 3.  HIV prevention among injection drug users: the need for integrated models.

Authors:  David S Metzger; Helen Navaline
Journal:  J Urban Health       Date:  2003-12       Impact factor: 3.671

4.  "Vivo para consumirla y la consumo para vivir" ["I live to inject and inject to live"]: high-risk injection behaviors in Tijuana, Mexico.

Authors:  Steffanie A Strathdee; Wendy Davila Fraga; Patricia Case; Michelle Firestone; Kimberly C Brouwer; Saida Gracia Perez; Carlos Magis; Miguel Angel Fraga
Journal:  J Urban Health       Date:  2005-09       Impact factor: 3.671

Review 5.  Update and overview of practical epidemiologic aspects of HIV/AIDS among injection drug users in the United States.

Authors:  Scott S Santibanez; Richard S Garfein; Andrea Swartzendruber; David W Purcell; Lynn A Paxton; Alan E Greenberg
Journal:  J Urban Health       Date:  2006-01       Impact factor: 3.671

Review 6.  Prevention and treatment of hepatitis C in injection drug users.

Authors:  Brian R Edlin
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

7.  Organizational issues in the implementation of a hospital-based syringe exchange program.

Authors:  Carmen L Masson; James L Sorensen; Nina Grossman; Karl A Sporer; Don C Des Jarlais; David C Perlman
Journal:  Subst Use Misuse       Date:  2010-05       Impact factor: 2.164

Review 8.  Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.

Authors:  Brian R Edlin; Thomas F Kresina; Daniel B Raymond; Michael R Carden; Marc N Gourevitch; Josiah D Rich; Laura W Cheever; Victoria A Cargill
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

Review 9.  Syringe availability as HIV prevention: a review of modalities.

Authors:  P Coffin
Journal:  J Urban Health       Date:  2000-09       Impact factor: 3.671

10.  A national physician survey on prescribing syringes as an HIV prevention measure.

Authors:  G E Macalino; D Dhawan Sachdev; J D Rich; C Becker; L J Tan; L Beletsky; S Burris
Journal:  Subst Abuse Treat Prev Policy       Date:  2009-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.